MPAN (Mitochondrial Membrane Protein-Associated Neurodegeneration, Mitochondrial CoA Synthesis Dysfunction) is the third most common NBIA disorder, caused by autosomal recessive mutations in the [COASY](/entities/coasy) gene (coenzyme A synthetase) or less commonly [MTOR](/entities/mtor). The disorder presents in adolescence or early adulthood with progressive dystonia, parkinsonism, and cognitive decline. MPAN is distinguished by mitochondrial respiratory chain dysfunction and iron-sulfur cluster assembly defects alongside the characteristic brain iron accumulation[@dusi2022].
| Feature | Detail |
|---------|--------|
| Gene | COASY (coenzyme A synthetase) |
| Inheritance | Autosomal recessive |
| Mechanism | Loss-of-function mutations |
| Allelic disorder | DOORS syndrome (some COASY variants) |
| Protein | CoA synthetase (bifunctional enzyme: pantothenate kinase + CoA synthetase domains) |
COASY encodes a bifunctional enzyme that catalyzes the final two steps of coenzyme A biosynthesis: (1) conversion of phosphopantetheine to dephospho-CoA, and (2) ATP-dependent phosphorylation of dephospho-CoA to CoA[@dusi2022]. Unlike PANK2 (which catalyzes step 1), COASY mutations cause deficiency in the final step of the pathway, creating a distinct biochemical phenotype from PKAN.
```mermaid
flowchart TD
A["COASY Biallelic Mutation"] --> B["Loss of CoA Synthetase Activity"]
MPAN (Mitochondrial Membrane Protein-Associated Neurodegeneration, Mitochondrial CoA Synthesis Dysfunction) is the third most common NBIA disorder, caused by autosomal recessive mutations in the [COASY](/entities/coasy) gene (coenzyme A synthetase) or less commonly [MTOR](/entities/mtor). The disorder presents in adolescence or early adulthood with progressive dystonia, parkinsonism, and cognitive decline. MPAN is distinguished by mitochondrial respiratory chain dysfunction and iron-sulfur cluster assembly defects alongside the characteristic brain iron accumulation[@dusi2022].
| Feature | Detail |
|---------|--------|
| Gene | COASY (coenzyme A synthetase) |
| Inheritance | Autosomal recessive |
| Mechanism | Loss-of-function mutations |
| Allelic disorder | DOORS syndrome (some COASY variants) |
| Protein | CoA synthetase (bifunctional enzyme: pantothenate kinase + CoA synthetase domains) |
COASY encodes a bifunctional enzyme that catalyzes the final two steps of coenzyme A biosynthesis: (1) conversion of phosphopantetheine to dephospho-CoA, and (2) ATP-dependent phosphorylation of dephospho-CoA to CoA[@dusi2022]. Unlike PANK2 (which catalyzes step 1), COASY mutations cause deficiency in the final step of the pathway, creating a distinct biochemical phenotype from PKAN.
CoA is essential for:
CoA deficiency impairs:
Iron-sulfur (Fe-S) clusters are essential cofactors for:
| Feature | MPAN Characteristics |
|---------|----------------------|
| Age of onset | Adolescence (10-20 years), occasionally earlier or later |
| Initial symptoms | Gait difficulties, dystonia, clumsiness |
| Core phenotype | Dystonia-parkinsonism (often mixed) |
| Progression | Slowly progressive over decades |
| Cognitive decline | Variable, typically mild-to-moderate |
| Psychiatric symptoms | Common (personality change, depression, OCD features) |
| MRI "eye of the tiger" | Rare or absent (unlike PKAN) |
| Optic atrophy | May occur |
| Seizures | Less common than in BPAN |
| Finding | MPAN Specifics |
|---------|----------------|
| Iron accumulation | Globus pallidus and substantia nigra (SN) |
| Eye of the tiger sign | Usually absent or mild |
| T2 signal changes | SWI hypointensity in GP/SN |
| White matter changes | May be present |
| Atrophy | Progressive caudate and putaminal atrophy |
| Approach | Status | Evidence |
|----------|--------|----------|
| CoA supplementation | Theoretical | CoA crosses BBB poorly; pantetheine/pantethine more viable |
| Pantethine (vitamin B5 derivative) | Experimental | Bypasses PANK2 defect; may partially compensate for COASY loss |
| Iron chelation | Case-by-case | If iron-mediated toxicity predominates |
| DBS (deep brain stimulation) | Used for dystonia | Case reports show benefit for severe dystonia |
| Physical/occupational therapy | Supportive | Maintains function |
| Psychiatric management | Symptomatic | SSRI/SNRI for depression/anxiety |
CoA biosynthesis involves five enzymatic steps, with COASY catalyzing the final two:
COASY is a bifunctional enzyme containing two domains:
| Domain | Function | Reaction |
|--------|----------|----------|
| Phosphopantetheine adenylyltransferase (PPAT) | First half of reaction | 4'-phosphopantetheine + ATP → dephospho-CoA + PPi |
| Dephospho-CoA kinase (DPCK) | Second half of reaction | dephospho-CoA + ATP → CoA + ADP |
The reaction mechanism:
CoA exists in multiple cellular pools:
| Pool | Location | Function | % of Total |
|------|----------|----------|------------|
| Mitochondrial | Matrix | Energy metabolism, TCA | 60-80% |
| Cytosolic | Cytosol | Biosynthetic reactions | 10-20% |
| Peroxisomal | Peroxisome | Fatty acid oxidation | 5-10% |
In MPAN, the mitochondrial pool is preferentially affected due to COASY's mitochondrial localization, explaining the prominent respiratory chain dysfunction[@marti2023].
| Feature | MPAN Characteristics |
|---------|----------------------|
| Age of onset | Adolescence (10-20 years), occasionally earlier or later |
| Initial symptoms | Gait difficulties, dystonia, clumsiness |
| Core phenotype | Dystonia-parkinsonism (often mixed) |
| Progression | Slowly progressive over decades |
| Cognitive decline | Variable, typically mild-to-moderate |
| Psychiatric symptoms | Common (personality change, depression, OCD features) |
| MRI "eye of the tiger" | Rare or absent (unlike PKAN) |
| Optic atrophy | May occur |
| Seizures | Less common than in BPAN |
Longitudinal studies show[@schneider2023]:
| Stage | Age | Features |
|-------|-----|----------|
| Preclinical | <10 years | Often asymptomatic, may have subtle findings |
| Early | 10-15 years | Gait disturbance, mild dystonia |
| Established | 15-25 years | Prominent dystonia-parkinsonism, cognitive changes |
| Advanced | >25 years | Severe motor disability, possible wheelchair use |
| Finding | MPAN Specifics |
|---------|----------------|
| Iron accumulation | Globus pallidus and substantia nigra (SN) |
| Eye of the tiger sign | Usually absent or mild |
| T2 signal changes | SWI hypointensity in GP/SN |
| White matter changes | May be present |
| Atrophy | Progressive caudate and putaminal atrophy |
| Condition | Distinguishing Features |
|-----------|------------------------|
| PKAN | Earlier onset, prominent eye of the tiger, pantothenate responsive |
| PLAN | Earlier onset, more severe phenotype |
| BPAN | Earlier onset, developmental delay, seizures |
| Kufor-Rakeb | Adult onset, levodopa responsive |
| PKAN-like (PLAN) | PANK2 negative but similar phenotype |
| Approach | Status | Evidence |
|----------|--------|----------|
| CoA supplementation | Theoretical | CoA crosses BBB poorly; pantetheine/pantethine more viable |
| Pantethine (vitamin B5 derivative) | Experimental | Bypasses PANK2 defect; may partially compensate for COASY loss |
| Iron chelation | Case-by-case | If iron-mediated toxicity predominates |
| DBS (deep brain stimulation) | Used for dystonia | Case reports show benefit for severe dystonia |
| Physical/occupational therapy | Supportive | Maintains function |
| Psychiatric management | Symptomatic | SSRI/SNRI for depression/anxiety |
Pantethine (the stable disulfide of pantetheine) can bypass both PANK2 and COASY defects:
Preliminary studies suggest modest benefit in some patients["@fourel2023"].
DBS has been used successfully in MPAN patients with severe dystonia[@giron2024]:
Currently, no MPAN-specific clinical trials are actively recruiting. However:
Priority biomarkers for MPAN include:
| Biomarker | Source | Purpose |
|-----------|--------|---------|
| CoA levels | Plasma/CSF | Disease monitoring |
| Acylcarnitines | Plasma | Metabolic status |
| Neurofilament light | Serum/CSF | Neuronal damage |
| Ferritin | Serum | Iron burden |
Preclinical gene therapy for MPAN uses:
Current status: Research phase, with studies in mouse models showing promise[@zhou2024].